Drew Davis, MD
Ophthalmology · Bedford, INNPI 1891086989
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,750 of the $4,568 with a category attached, or 60.2%. 22 manufacturers reported payments, led by The Cameron-ehlen Group, Inc. at 35.1% of the total. Reporting peaked in 2019 at $2,153 and has fallen 86.2% since, to $297 in 2025.
Across 75 payments — averaging $60.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- The Cameron-ehlen Group, Inc.$2K
- Carl Zeiss Meditec, Inc.$1K
- Alcon$442
- Johnson & Johnson Surgical Vision, Inc.$239
- Tarsus Pharmaceuticals, Inc.$196
- Boston Scientific$104
- plus $732 from 16 others
What the payments were for
- Food & beverage$1,81840%
- Education$2,75060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| The Cameron-ehlen Group, Inc. | 5 | $1,605 |
| Carl Zeiss Meditec, Inc. | 1 | $1,250 |
| Alcon | 16 | $442 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $239 |
| Tarsus Pharmaceuticals, Inc. | 12 | $196 |
| Boston Scientific | 4 | $104 |
| Staar Surgical Company | 1 | $92 |
| Sight Sciences, Inc. | 4 | $79 |
| Lumibird Medical Inc. | 1 | $78 |
| Kala Pharmaceuticals, Inc. | 5 | $78 |
| Bausch & Lomb Americas Inc. | 3 | $73 |
| AbbVie(2 entities) | 4 | $64 |
| Novartis | 3 | $61 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $34 |
| Astellas Pharma US Inc | 1 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
| Rxsight Inc | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Thea Pharma Inc. | 1 | $19 |
| Ziemer USA | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,568 in reported general payments places this provider in the 80th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 15 | $10,831 |
| XiidraLifitegrast | 15 | $10,744 |
| Cyclosporine | 17 | $5,667 |
| AlrexLoteprednol Etabonate | 12 | $3,547 |
| Prednisolone Acetate | 80 | $3,500 |
| Latanoprost | 286 | $3,332 |
| MoxifloxacinMoxifloxacin Hcl | 75 | $2,214 |
| Ketorolac Tromethamine | 74 | $2,188 |
| Brimonidine Tartrate | 41 | $2,008 |
| Travoprost | 18 | $1,843 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $1,667 |
| ErythromycinErythromycin Base | 122 | $1,526 |
| Fluorometholone | 12 | $1,176 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $1,093 |
| Timolol Maleate | 77 | $1,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $64 | $10,83115 claims |
| Bausch & Lomb Americas Inc.Xiidra | $73 | $10,74415 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex | $34 | $3,54712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Bedford
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.